NONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: THE THERAPEUTIC WINDOW
|
|
- Lester Cain
- 6 years ago
- Views:
Transcription
1 Rev. Med. Chir. Soc. Med. Nat., Iaşi 2016 vol. 120, no. 1 INTERNAL MEDICINE UPDATES NONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: THE THERAPEUTIC WINDOW Mihaela Dimache 1,2*, Irina Gîrleanu 1,2, Eleonora Carpov 2, Anca Trifan 1,2, C. Stanciu 2 Gr. T. Popa University of Medicine and Pharmacy-Iaș i Faculty of Medicine 1. Department of Gastroenterology 2. Institute of Gastroenterology and Hepatology, Iaș i *Corresponding author: mimidimache@yahoo.com NONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: THE THERA- PEUTIC WINDOW (Abstract): For over 30 years, nonselective beta-blockers (NSBB) have been successfully used for preventing variceal bleeding in patients with cirrhosis and portal hypertension. Nevertheless, recent studies suggest that NSBB may be effective only within a particular therapeutic window in patients with advanced liver disease. Outside of this wi n- dow, in early stages of cirrhosis and in very advanced cirrhosis, NSBB may be ineffective and even potentially harmful. In this paper we review the beneficial effects and potential harms of beta-blocker therapy in cirrhosis and underline the most recent recommendations for their use in very advanced cases of liver disease. Keywords: LIVER CIRRHOSIS; BE- TA-BLOCKERS; THERAPEUTIC WINDOW. Pathophysiological basis for using nonselective beta-blockers (NSBB) in patients with cirrhosis. The development of portal hypertension in cirrhosis is mainly due to: a) An increase in resistance to portal blood flow, because of architectural modifications in the liver, and b) An increase in portal territory blood flow, due to splanchnic arteriolar vasodilatation. Therefore, NSBB goal in cirrhosis is to reduce portal pressure by two essential mechanisms: a) ß1- adrenergic blockade, which decreases cardiac output, leading to reduced portal blood flow, and b) ß2- adrenergic blockade, followed by an increase in arterial splanhnic resistance. How did NSBB occur in the treatment of cirrhotic patient. The study of Lebrec et al. (3) published in 1981 in New England Journal of Medicine was the key-point in establishing the role of NSBB in the secondary prevention of variceal hemorrhage. In 1987, the study of Pascal et al.(4) underlines the role of NSBB in the primary prophylaxis of variceal bleeding. In 1991, Poynard et al.(5) meta-analysis together with other studies establishes that NSBB represent the first line therapy both in primary and in secondary prophylaxis of variceal hemorrhage. The most important studies supporting NSBB usage in the treatment of cirrhotic patient are summarized by Phillip S. Ge., in 23
2 Mihaela Dimache et al. Journal of Hepatology from 2014 (1). The indications of NSBB in cirrhosis 1. Primary prevention of variceal hemorrhage: a) In cirrhotic patients with medium or large esophageal varices, NSBB lower the risk of first variceal bleeding (from 30% to 14%, compared to placebo) (6). b) Primary prevention is not recommended in cirrhotic patients without esophageal varices, whatever the value of hepatic venous pressure gradient (HVPG). 2. Secondary prevention of variceal hemorrhage: NSBB reduce the rate of variceal rebleeding from 60% to approximately 40%. 3. Other benefits: NSBB might prevent the development of spontaneous bacterial peritonitis (SBP), by reducing intestinal permeability and bacterial translocation. I. Pre-primary prophylaxis (to prevent the development of esophageal varices) There are no data to confirm the benefit of using NSBB to prevent the development of esophageal varices, the most efficient method being the treatment of liver disease. Studies showed that in patients without esophageal varices, NSBB (like timolol) have no role in preventing the development of esophageal varices, and the side effects are more frequent (7). In conclusion, NSBB are not recommended in this set of patients. II. Primary prevention (the prevention of first episode of variceal bleeding) An important meta-analysis of 11 trials including almost 1200 patients evaluated the role of NSBB (propranolol or nadolol) in the primary prophylaxis of variceal haemorrhage (8). The results showed that in cirrhotic patients with medium or large esophageal varices NSBB lower the risk of first variceal bleeding (from 30% to 14%, compared to placebo) (6). Other studies show that one bleeding episode is avoided for every ten patients treated with NSBB. In conclusion, NSBB reduce the rate of bleeding-related mortality compared to the control group (9). Upon the size of esophageal varices, the recommendations are as follows: According to Baveno VI Consensus, in cirrhotic patients with medium or large esophageal varices NSBB are recommended to prevent the first episode of variceal hemorrhage (6). Still, the risk of bleeding depends not only upon the size of esophageal varices, but also upon the presence of the marks of bleeding ( red signs ) on the varices and on the severity of liver disease. In patients with compensated liver disease (Child-Pugh A) and small esophageal varices without red signs, the risk of bleeding is 6%, while the patients with Child- Pugh C cirrhosis, with large esophageal varices with red signs have a risk of bleeding of 76% (10). The set of cirrhotic patients with small esophageal varices are classified in two groups depending on the other factors which influence the risk of bleeding: 1. In patients with small esophageal varices and low risk of bleeding, which means without red signs and in the absence of severe liver disease (CHILD A), there are insufficient data that the use of NSBB would prevent the progression of esophageal varices. These patients may use NSBB to prevent the esophageal haemorrhage just in some individualized cases. The patients with small esophageal varices without therapy with NSBB must have endoscopy every 2 years, to evaluate the progression of 24
3 Nonselective beta-blockers in patients with cirrhosis: the therapeutic window esophageal varices (11-13). 2. In cirrhotic patients with small esophageal varices and high risk of bleeding, meaning the presence of red signs and/or the presence of severe liver disease (CHILD-PUGH B or C), the treatment with NSBB is recommended (6,13). III. Secondary prophylaxis of variceal bleeding Secondary prevention means the prevention of rebleeding from esophageal varices, being addressed to those cirrhotic patients who have already had an episode of variceal haemorrhage. Studies showed that patients who survive an episode of variceal haemorrhage have a high risk of rebleeding and death. In this set, untreated patients have a rebleeding rate of 60% at 1-2 years, with a mortality of 20-50% (14). Besides, the prevention of rebleeding from esophageal varices was the first confirmed indication for using NSBB in the treatment of cirrhosis (the study of Lebrec et al. from 1981) (3). It was demonstrated in trials that NSBB reduce the rebleeding rate from 60% to almost 40% (3,5,8). According to the last guidelines, the combination of NSBB and band ligation is considered the maximal therapy for preventing rebleeding from esophageal varices. This provides the lowest rates of rebleeding, without major differences between the survival rates (compared to the patients treated only with NSBB). The early administration of NSBB may reduce the risk of bleeding till endoscopic band ligation. (6,15). Other benefits of NSBB in cirrhosis include the prevention of other complications, like bleeding from portal gastropathy, the occurrence of ascites and of SBP (3,17). The control of the efficiency of NSBB in cirrhosis targets: a) A hemodynamic response to NSBB means a decrease in the HVPG below 12 mmhg or of 20% of the baseline value; b) The adrenergic response to NSBB is defined as a decrease in the heart rate (measured h after drug administration) of 25% of the baseline value; c) The dose of NSBB is decided according to: a decrease in the heart rate (HR) of 25% of the basal value; the value of HR at rest not below 55/min; pay attention to the occurrence of side effects (3). The side effects of NSBB a) Cardiac: the exacerbation or precipitation of heart failure, symptomatic bradycardia, high grade heart block. The acute withdrawal of beta-blocker therapy can lead to accelerated angina, myocardial infarction and sudden death! b) Pulmonary: increased airways resistance in patients with bronchospasm c) Circulatory: the exacerbation of peripheral artery disease (claudication, absent pulses, cyanosis and gangrene) d) Metabolic: in patients with diabetes mellitus, risk of severe insulin-induced hypoglycemia e) Other: depression, fatigue and sexual dysfunction. Contraindications to NSBB in cirrhotic patients These may be classified as follows: 1) General contraindications a) Absolute severe heart failure, advanced heart block; b) Relative moderate chronic heart failure, asthma, chronic obstructive pulmonary disease, peripheral arterial disease, Raynaud syndrome, insulin-treated diabetes mellitus. 25
4 Mihaela Dimache et al. 2) Cirrhosis-related contraindications a) Portopulmonary hypertension; b) Refractory ascites. Is the therapy with NSBB in cirrhosis safe? How did this question occur? The same authors whose studies established the use of NSBB in the treatment of cirrhosis raised this problem! In 2010, the study of Serste et al. (17,18) published in Hepatology concluded that NSBB should be contraindicated in cirrhotic patients with refractory ascites, leading to a shortening of survival. Other authors, Wong and Salerno (19) showed that, regardless the design of the study, the safety of the treatment with propranolol in cirrhotic patients with refractory ascites is a problem. In 2011, another trial of Lebrec et al. (3) postulated that NSBB are associated with the paracentesis-induced circulatory dysfunction (PICD), leading to a reduced survival rate in this group of patients. The therapeutic window hypothesis. Recent studies of Krag et al. (20) suggest that the efficiency of NSBB manifests just during a window in the disease, named therapeutic window, in those patients with advanced cirrhosis. Outside of this window, the therapy with NSBB may be ineffective in early stages of cirrhosis and potentially harmful in advanced cirrhosis (1). Defining the term of the therapeutic window. In early stages of cirrhosis, NSBB have no beneficial effect on survival and the adverse events may be more frequent (7). These stages are defined by the following parameters: the esophageal varices are small or absent; intact cardiac reserve; sympathetic nervous system (SNS) and reninangiotensin-aldosterone system (RAAS) have baseline activity; the risk of gut bacterial translocation is low, and the risk of mortality is also law (7). In decompensated cirrhosis, NSBB improves the survival rate, lowering the rate of esophageal bleeding and of bacterial translocation. This stage of cirrhosis has the following characteristics: medium or large esophageal varices; ascites; the cardiac reserve is intact, but declining; SNS and RAAS have increased but not maximal activity, and the risk of bacterial translocation and of mortality are increased (1). The final (terminal) stages of cirrhosis are characterized by refractory ascites; impaired cardiac reserve, with baseline hypotension; SNS and RAAS are maximally stimulated and can no longer maintain adequate blood pressure (BP); high risk of gut bacterial translocation and of mortality (7). In these stages, NSBB decrease the rate of survival as a result of the negative impact on cardiac reserve, lowering the perfusion of vital organs and precipitating the hepatorenal syndrome (HRS). Why NSBB are not indicated in refractory ascites? The study of Serste et al. (18) from 2011 show that in cirrhotic patients with refractory ascites NSBB may cause a higher risk of paracentesis-induced circulatory dysfunction, thus reducing the rate of survival (2). NSBB (like propranolol) would prevent the adaptive hemodynamic response after large volume paracentesis, subsequently inducing PICD. The factors which close the therapeutic window are: a) The occurrence of refractory ascites and of SBP; b) Systolic BP below 95 mmhg; c) The presence of symptoms of orthostatic hypotension; 26
5 Nonselective beta-blockers in patients with cirrhosis: the therapeutic window d) The occurrence of septic episodes; e) Increased levels of serum creatinine. The presented data show that the presence of medium or large esophageal varices opens the window of opportunity, which will be closed by the occurrence of refractory ascites, decreased medium BP and/or HRS. Taking into consideration the duration relatively limited of the therapeutic window, some authors agree that NSBB should not be recommended in patients with low medical compliance and/or poor medical follow-up (21,22). The initiation and continuation of NSBB therapy is ideal in those patients with home monitoring of BP and HR and who will have a close follow-up meaning frequent medical visits (23). Concerning the therapeutic window hypothesis, the results from studies and the existing evidences are still conflicting. For example, the study of Galbois et al. (24) published in Hepatology contradicts some of the previous data, suggesting that NSBB are not associated with an inadequate hemodynamic response in patients with cirrhosis and severe sepsis. For now, the recommendations of Baveno VI Consensus (6) are the following: 1) The safety of beta-blockers administration in cirrhotic patients with refractory ascites and/or hepatorenal syndrome was not demonstrated; 2) The patients with refractory ascites must be intensively monitored; if systemic hypotension or azotemia occur, we must reduce the dosage of NSBB or even discontinue the BB therapy; 3) If NSBB therapy is discontinued, the patient will need esophageal band ligation for preventing variceal bleeding; 4) Until practical data from randomised trials arrive, NSBB must be discontinued or the dose must be reduced in patients with refractory ascites if: systolic BP is below 90 mmhg; serum creatinine is raising and/or hyponatremia below 130 mmol/l occurs; 5) The consequence of discontinuing the BB therapy on the prevention of esophageal bleeding is not known; 6) If variceal bleeding or SBP occur after discontinuing the BB therapy, we may restart the treatment if the above parameters became normal. CONCLUSIONS In conclusion, the therapy with NSBB requires special attention in two clinical settings: a) Decompensated cirrhosis in terminal stage, and b) Refractory ascites. It remains unclear if, after closing the therapeutic window of NSBB in cirrhosis, this would be a definitive closure or not, referring to the possibility of restarting the beta-blocker medication after a period of time. REFERENCES 1. Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J. Hepatol 2014; 60: Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010; 59: Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med 1981; 305:
6 Mihaela Dimache et al. 4. Pascal JP, Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987; 317: Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, et al. Beta-adrenergic- antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med 1991; 324: de Franchis R Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015; 63(3): Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353: D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidencebased approach. Sem Liv Dis. 1999; 19: La Mura V, Tosetti G, Primignani M, et al. Use of non-selective beta blockers in cirrhosis: the evidence we need before closing (or not) the window. World J Gastroenterol. 2015; 21(8): Krag A, Wiest R, Albillos A, Gluud LL. The window hypothesis: haemodynamic and nonhaemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut. 2012; 61: Tsochatzis EA, Bosch J, Burroughs AK. New therapeutic paradigm for patients with cirrhosis. Hepatology 2012; 56: Merkel C, Marin R, Angeli P, Zanella P, Felder M, Bernardinello E, Cavallarin G, Bolognesi M, Donada C, Bellini B, Torboli P, Gatta A. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterol 2004; 127: Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010; 362: Mellinger JL, Volk ML. Multidisciplinary management of patients with cirrhosis: a need for care coordination. Clin Gastroenterol Hepatol 2013; 11: Senzolo M, Cholongitas E, Burra P, Leandro G, Thalheimer U, Patch D, Burroughs AK. beta- Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009; 29: Abraldes JG, Tandon P. The use of beta-blockers in advanced cirrhosis- where do we stand? Curr Hepatology Rep 2015; 14: Sersté T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, Moreau R, Lebrec D. Deleterious effects of beta blockers on survival in patients with cirrhosis and refractory ascites. Hepatol 2010; 52: Serste T, Francoz C, Durand F, Rautou PE, Melot C, Valla D, et al. Betablockers cause paracentesisinduced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol 2011; 55: Wong F, Salerno F. Beta-blockers in cirrhosis: friend and foe? Hepatol 2010; 52: Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010; 59: Sharma C, Fletcher KE, Zhang D, Kun YF, et al. Continuity of outpatient and inpatient care by primary care physicians for hospitalized older adults. JAMA 2009; 301: Dănulescu RM, Stanciu C, Trifan A: Evaluation of prognostic factors in decompensated liver cirrhosis with ascites and spontaneous bacterial peritonitis. Rev Med Chir 2015; 119 (4): Morando F, Maresio G, Piano S, Fasolato S, et al. How to improve care in outpatients with cirrhosis and ascites: a new model of care coordination by consultant hepatologists. J Hepatol 2003; 59: Galbois A, Das V, Thabut D, Maury E, Ait-Oufella H, Housset C, et al. Beta-blockers have no effect on outcomes in patients with cirrhosis and severe infections. Hepatol. 2011; 53:
Beta-blockers in cirrhosis: Cons
Beta-blockers in cirrhosis: Cons Eric Trépo MD, PhD Dept. of Gastroenterology. Hepatopancreatology and Digestive Oncology. C.U.B. Hôpital Erasme. Université Libre de Bruxelles. Bruxelles. Belgium Laboratory
More informationBETA-BLOCKERS IN CIRRHOSIS.PRO.
BETA-BLOCKERS IN CIRRHOSIS.PRO. Angela Puente Sánchez. MD PhD Hepatology Unit. Gastroenterology department Marques de Valdecilla University Hospital. Santander INTRODUCTION. Natural history of cirrhosis
More informationREVIEW. Ariel W. Aday, M.D.,* Nicole E. Rich, M.D.,* Arjmand R. Mufti, M.D., and Shannan R. Tujios, M.D.
REVIEW CON ( The Window Is Closed ): In Patients With Cirrhosis With Ascites, the Clinical Risks of Nonselective beta-blocker Outweigh the Benefits and Should NOT Be Prescribed Ariel W. Aday, M.D.,* Nicole
More informationPrimary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation
Primary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation Siwaporn Chainuvati, MD Faculty of Medicine Siriraj Hospital Outline Natural history of esophageal varices Which
More informationth Annual AISF Meeting 44 th th th, 2011 Rome, February 23 rd -26
44 th 44 th Annual AISF Meeting Rome, February 23 rd -26 th th, 2011 Update on the Baveno Consensus Conference Roberto de Franchis Department of of Clinical Sciences, University of of Milan, Head, Gastroenterology
More informationVariceal bleeding. Mainz,
Variceal bleeding Mainz, 21.09.2008 Risk of complications 5 years 10 years Ascites 10 % 25 % HCC 10 % 25 % Bleeding < 5 % 5-10 % Enceph. < 5 % < 5 % Typical situation : Mortality 10 % to 40 % Sequence
More informationCarvedilol or Propranolol in the Management of Portal Hypertension?
Evidence Based Case Report Carvedilol or Propranolol in the Management of Portal Hypertension? Arranged by: dr. Saskia Aziza Nursyirwan RESIDENCY PROGRAM OF INTERNAL MEDICINE DEPARTMENT UNIVERSITY OF INDONESIA
More informationEsophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph
Esophageal Varices Beta-Blockers or Band Ligation Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation? Risk of esophageal variceal
More informationIs pharmacological therapy the best choice for primary prevention of variceal hemmorhaging in patients with hepatic cirrhosis?
Controversies en Gastroenterology Is pharmacological therapy the best choice for primary prevention of variceal hemmorhaging in patients with hepatic cirrhosis? Rolando José Ortega Quiroz, MD, 1 Adalgiza
More informationTreatment of portal hypertension in the light of the Baveno VI Consensus Conference
r e v I E w A R T I C l e S Curierul medical, December 2015, Vol. 58, No 6 Treatment of portal hypertension in the light of the Baveno VI Consensus Conference E. Tcaciuc Department of Internal Medicine,
More informationEvidence-Base Management of Esophageal and Gastric Varices
Evidence-Base Management of Esophageal and Gastric Varices Rino Alvani Gani Hepatobiliary Division Department of Internal Medicine Faculty of Medicine Universitas Indonesia Cipto Mangunkusumo National
More informationEdinburgh Research Explorer
Edinburgh Research Explorer Carvedilol is associated with improved survival in patients with liver cirrhosis and ascites Citation for published version: Sinha, R, Lockman, KA, Mallawaarachchi, N, Robertson,
More informationManagement of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University
Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments
More informationCARLO MERKEL, MASSIMO BOLOGNESI, DAVID SACERDOTI, GIANCARLO BOMBONATO, BARBARA BELLINI, RAFFAELLA BIGHIN, AND ANGELO GATTA
The Hemodynamic Response to Medical Treatment of Portal Hypertension as a Predictor of Clinical Effectiveness in the Primary Prophylaxis of Variceal Bleeding in Cirrhosis CARLO MERKEL, MASSIMO BOLOGNESI,
More informationAre the benefits of beta blockers in cirrhotics only related to decreased portal hypertension?
Editorial Page 1 of 5 Are the benefits of beta blockers in cirrhotics only related to decreased portal hypertension? Felix Piecha 1, Sebastian Mueller 2 1 Department of Medicine, University Medical Center
More informationCase Report: Refractory variceal bleeding Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France
Case Report: Refractory variceal bleeding Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France Thank you to Marika Rudler, Dominique Thabut, Adrian Gadano, and Jaime Bosch for
More informationACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis
ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis Guadalupe Garcia-Tsao, M.D., 1 Arun J. Sanyal, M.D., 2 Norman D. Grace,
More informationTerlipressin: An Asset for Hepatologists!
DIAGNOSTIC AND THERAPEUTIC ADVANCES IN HEPATOLOGY Terlipressin: An Asset for Hepatologists! S.K. Sarin and Praveen Sharma One Case Scenario A 48-year-old male with alcoholic cirrhosis who was abstinent
More informationCost-effectiveness analysis of beta-blockers vs endoscopic surveillance in patients with cirrhosis and small varices
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v20.i30.10464 World J Gastroenterol 2014 August 14; 20(30): 10464-10469 ISSN 1007-9327
More informationVirtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12:
Virtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12: 805-809. CLINICAL PEARL Indications for Use of TIPS in Treating Portal Hypertension Elizabeth C. Verna,
More informationBeta-blocker plus nitrates for secondary prevention of variceal bleeding (Protocol)
Beta-blocker plus nitrates for secondary prevention of variceal bleeding (Protocol) Sharma BC, Gluud LL, Sarin SK This is a reprint of a Cochrane protocol, prepared and maintained by The Cochrane Collaboration
More informationInitial approach to ascites
Ascites: Filling and Draining the Water Balloon Common Pathogenesis in Refractory Ascites, Hyponatremia, and Cirrhosis intrahepatic resistance sinusoidal portal hypertension Splanchnic vasodilation (effective
More informationDiagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion
5 th AISF Post-Meeting Course Diagnostic and Therapeutic Invasive Procedures in Hepatology Rome, February 25 th Diagnostic Procedures Measurement of Hepatic venous pressure in management of cirrhosis Clinician
More informationAscites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology
Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant
More informationCare of the Patient With Cirrhosis
REVIEW Care of the Patient With Cirrhosis Anitha Yadav, M.D., and Hugo E. Vargas, M.D. Caring for patients with cirrhosis involves multidisciplinary and timely management of several complications while
More informationBeta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis
The new england journal of medicine original article Beta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis Roberto J. Groszmann, M.D., Guadalupe Garcia-Tsao, M.D., Jaime Bosch, M.D.,
More informationContraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:
Contraindications Absolute Relative Primary prevention variceal bleeding HCC if centrally located Active congestive heart failure Obstruction all hepatic veins Thomas D. Boyer, M.D. University of Arizona
More informationGI bleeding in chronic liver disease
GI bleeding in chronic liver disease Stuart McPherson Consultant Hepatologist Liver Unit, Freeman Hospital, Newcastle upon Tyne and Institute of Cellular Medicine, Newcastle University. Case 54 year old
More informationHemorragia por várices gastroesofágicas en la cirrosis
Hemorragia por várices gastroesofágicas en la cirrosis Referencias 1. Garcia-Tsao G, Sanyal AJ, Grace ND,Carey W, Practice Guidelines Committee of the American Association for the Study of Liver Diseases,
More informationConflict of interest disclosures. Complications of end stage liver disease. None. The many complications of Cirrhosis. Portal Hypertension.
Complications of end stage liver disease Conflict of interest disclosures None Amir Qamar, MD Instructor of Medicine Brigham and Women s s Hospital Harvard Medical School Boston, MA 02115 The many complications
More informationTransfusion strategies in patients with cirrhosis: less is more. 1. Department of Gastroenterology, Hillingdon Hospital, London, UK
Transfusion strategies in patients with cirrhosis: less is more Evangelia M. Fatourou 1, Emmanuel A. Tsochatzis 2 1. Department of Gastroenterology, Hillingdon Hospital, London, UK 2. UCL Institute for
More informationCauses of Liver Disease in US
Learning Objectives Updates in Outpatient Cirrhosis Management Jennifer Guy, MD MAS Director, Liver Cancer Program California Pacific Medical Center guyj@sutterhealth.org Review cirrhosis epidemiology,
More informationPrevention of the development of varices and first portal hypertensive bleeding episode
Best Practice & Research Clinical Gastroenterology Vol. 21, No. 1, pp. 31e42, 2007 doi:10.1016/j.bpg.2006.06.001 available online at http://www.sciencedirect.com 3 Prevention of the development of varices
More informationLong term administration of human albumin improves survival in patients with cirrhosis and refractory ascites
Received: 3 May 2018 Revised: 2 August 2018 Accepted: 12 September 2018 DOI: 10.1111/liv.13968 CIRRHOSIS AND LIVER FAILURE Long term administration of human albumin improves survival in patients with cirrhosis
More informationHepatorenal Syndrome
Necker Seminars in Nephrology Institut Pasteur Paris, April 22, 2013 Hepatorenal Syndrome Dr. Richard Moreau 1 INSERM U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, 2 Université Paris Diderot
More informationPortal hypertension is the main complication of cirrhosis
GASTROENTEROLOGY 2001;120:726 748 Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis GUADALUPE GARCIA TSAO
More informationManagement of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy
Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:
More informationVARICEAL BLEEDING. Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta.
VARICEAL BLEEDING Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta Disclosures: None OUTLINE Pathophysiology of portal hypertension Splanchnic
More informationManagement of Cirrhosis Related Complications
Management of Cirrhosis Related Complications Ke-Qin Hu, MD, FAASLD Professor of Clinical Medicine Director of Hepatology University of California, Irvine Disclosure I have no disclosure related to this
More informationCost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleeding Raines D L, Dupont A W, Arguedas M R
Cost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleeding Raines D L, Dupont A W, Arguedas M R Record Status This is a critical abstract of an economic
More informationDRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)
DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS) Beta-blockers have been widely used in the management of angina, certain tachyarrhythmias and heart failure, as well as in hypertension. Examples
More informationENDOSCOPIC LIGATION OF ESOPHAGEAL VARICES LONG TERM RESULTS
ENDOSCOPIC LIGATION OF ESOPHAGEAL VARICES LONG TERM RESULTS R. Nikolov, St.Ivan Rilski University Hospital, Clinic of Gastroenterology Sofia, Bulgaria, Medical University Sofia, Bulgaria Contact: R. Nikolov,
More informationThe Value of Renal Artery Resistive Indices: Association with
The Value of Renal Artery Resistive Indices: Association with Esophageal Variceal Bleeding in Patients with Alcoholic Cirrhosis 1 Joo Nam Byun, M.D., Dong Hun Kim, M.D. Purpose: To determine whether resistive
More informationCIRCULATORY AND RENAL FAILURE IN CIRRHOSIS
CIRCULATORY AND RENAL FAILURE IN CIRRHOSIS Pere Ginès, MD Liver Unit, Hospital Clínic Barcelona, Catalunya, Spain CIRCULATORY AND RENAL FAILURE IN CIRRHOSIS Hecker R and Sherlock S, The Lancet 1956 RENAL
More informationCirrhosis is the irreversible fibrosis of the liver, the end stage
The new england journal of medicine Review Article Edward W. Campion, M.D., Editor Treatment of Patients with Cirrhosis Phillip S. Ge, M.D., and Bruce A. Runyon, M.D. Cirrhosis is the irreversible fibrosis
More informationJOURNAL PRESENTATION. Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013
JOURNAL PRESENTATION Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013 THE COMBINATION OF OCTREOTIDE AND MIDODRINE IS NOT SUPERIOR TO ALBUMIN IN PREVENTING RECURRENCE OF ASCITES AFTER LARGE-VOLUME PARACENTESIS
More informationA randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients
Annals of Hepatology 2003; 2(1): January-March: 36-40 Original Article Annals of Hepatology A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients
More informationCirrhosis is the end stage of any chronic liver
LIVER FAILURE/CIRRHOSIS/PORTAL HYPERTENSION Quantitative Histological-Hemodynamic Correlations in Cirrhosis Supatsri Sethasine, 1 Dhanpat Jain, 2 Roberto J. Groszmann, 1 and Guadalupe Garcia-Tsao 1 We
More informationINCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS
INCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS Yoshida H et al (1993)* Deschenes M et al (1999)** Strauss E et al (1993) Borzio M et al (2002) PATIENTS 1140 140 170 405 INFECTIONS 15.4% 20% 47% 34% * Many
More informationORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:703 708 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Compliance With Practice Guidelines and Risk of a First Esophageal Variceal Hemorrhage in Patients
More informationNorepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome
Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome Disclosure I have no conflicts of interest to disclose Name: Margarita Taburyanskaya Title: PharmD, PGY1 Pharmacy Practice Resident
More informationHepatorenal syndrome. Jan T. Kielstein Departent of Nephrology Medical School Hannover
Hepatorenal syndrome Jan T. Kielstein Departent of Nephrology Medical School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical presentation of HRS
More informationHemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: Systematic review and meta-analysis
420 ORIGINAL ARTICLE July-August, Vol. 13 No. 4, 2014: 420-428 Hemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: Systematic review and meta-analysis Nancy Aguilar-Olivos,* Miguel
More informationInvasive Evaluation of Portal Hypertension. Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan
Invasive Evaluation of Portal Hypertension Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan Vincenzo La Mura, MD, PhD Dipartimento di scienze Biomediche per la
More informationMANAGING END STAGE LIVER DISEASE IN RESOURCE LIMITED SETTINGS
MANAGING END STAGE LIVER DISEASE IN RESOURCE LIMITED SETTINGS Mark W. Sonderup Division of Hepatology and Liver Laboratory Department of Medicine University of Cape Town & Groote Schuur Hospital Cirrhosis..
More informationThe effect of bacterial infections in cirrhotic patients with esophageal variceal bleeding
364 Gan Z-H, et al., 2014; 13 (3): 364-369 ORIGINAL ARTICLE May-June, Vol. 13 No. 3, 2014: 364-369 The effect of bacterial infections in cirrhotic patients with esophageal variceal bleeding Zuo-Hua Gan,*,,
More informationEuropean. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes
supported by from Gilea Quantification of fibrosis and cirrhosis outcomes th 5 European 5 European Young Hepatologists Workshop Young Hepatologists Workshop August, 27-29. 2015, Moulin de Vernègues Vincenza
More informationPropranolol Treatment is Associated with Better Survival in Cirrhotic Patients with Hepatic Encephalopathy
Article Propranolol Treatment is Associated with Better Survival in Cirrhotic Patients with Hepatic Encephalopathy Pei-Chang Lee 1,2,3,+, Yu-Ju Chen 1,4,+, Yueh-Ching Cho 1,4,6, Kuei-Chuan Lee 2,3, Ping-Hsien
More informationHaemodynamic parameters predicting variceal haemorrhage and survival in alcoholic cirrhosis
Q J Med 1998; 91:19 25 Haemodynamic parameters predicting variceal haemorrhage and survival in alcoholic cirrhosis A.J. STANLEY, I. ROBINSON, E.H. FORREST, A.L. JONES and P.C. HAYES From the Department
More informationCLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed?
CLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed? The Hospitalist. 2016 August;2016(8) Author(s): Raj Sehgal, MD; Joshua Hanson, MD, MPH; Division OF The
More informationBarbara Rus Gadžijev Peter Popovič Klinični inštitut za radiologijo UKC Ljubljana
STROKOVNI SESTANEK ZDRUŽENJA HEMATOLOGOV SLOVENIJE IN ZDRUŽENJA ZA TRANSFUZIJSKO MEDICINO, Terme Zreče, 17.-18.4.2015 Barbara Rus Gadžijev Peter Popovič Klinični inštitut za radiologijo UKC Ljubljana goals,
More informationManagement of the Cirrhotic Patient in the ICU
Management of the Cirrhotic Patient in the ICU Peter E. Morris, MD Professor & Chief, Pulmonary, Critical Care and Sleep Medicine University of Kentucky Conflict of Interest Funding US National Institutes
More informationChapter 2 Natural History and Stages of Cirrhosis
Chapter 2 Natural History and Stages of Cirrhosis Gennaro D Amico Introduction The natural history of cirrhosis is characterized by an asymptomatic phase, referred to as compensated cirrhosis, followed
More informationFilippo Schepis, MD Università degli Studi di Modena e Reggio Emilia
Filippo Schepis, MD Università degli Studi di Modena e Reggio Emilia Il sottoscritto dichiara di non aver avuto/di aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
More informationComplication of Portal Hypertension: should the patients in the waiting list be treated differently?
Wilma Debernardi Venon Gastroepatologia, Az. Osp. San Giovanni Battista ditorino Complication of Portal Hypertension: should the patients in the waiting list be treated differently? Il sottoscritto dichiara
More informationProf. Mohammad Umar. MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA
Prof. Mohammad Umar MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA Chairman and Head Department of Medicine Rawalpindi Medical College, Rawalpindi. Consultant Gastroenterologist / Hepatologist
More informationWhat Have We Accomplished (and What Lies Ahead)
LECTURE What Have We Accomplished (and What Lies Ahead) Roberto de Franchis INTRODUCTION The idea of holding consensus meetings on portal hypertension was born in 1986, when Andrew Burroughs organised
More informationEvaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
More informationPPCR. of Clinical Research A Global Journal in Clinical Research
Principles and Practice of Clinical Research A Global Journal in Clinical Research PPCR ISSN: 2378-1890 Jan-Jun, 2017;3(1) ppcr.org/journal/home-current Study design Propranolol versus carvedilol for the
More informationMichele Bettinelli RN CCRN Lahey Health and Medical Center
Michele Bettinelli RN CCRN Lahey Health and Medical Center Differentiate the types of varices Identify glue preparations utilized when treating gastric varices Review the process of glue administration
More informationOriginal article Correlation between serum-ascites albumin concentration gradient and endoscopic parameters of portal hypertension
Kathmandu University Medical Journal (005), Vol. 3, No., Issue, 37-333 Original article Correlation between serum-ascites albumin concentration gradient and endoscopic parameters of portal hypertension
More informationDr. Vishaal Bhat. anti-adrenergic drugs
Dr. Vishaal Bhat anti-adrenergic drugs Divisions of human nervous system Human Nervous system Central Nervous System Peripheral Nervous System Autonomic Nervous System Nervous system Includes neurons and
More informationCIRRHOSIS Definition
Cirrhosis Update Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology Weill Cornell Medical College CIRRHOSIS Definition Irreversible fibrous
More informationPrevention and treatment of variceal haemorrhage in 2017
Received: 12 October 2016 Accepted: 19 October 2016 DOI: 10.1111/liv.13277 REVIEW ARTICLE Prevention and treatment of variceal haemorrhage in 2017 Felix Brunner 1 Annalisa Berzigotti 1 Jaime Bosch 1,2
More informationOriginal Article. QT interval prolongation: a risk factor for development of hepatorenal syndrome in cirrhotic patients with acute variceal bleeding
Tropical Gastroenterology 2014;35(3):157 163 Original Article QT interval prolongation: a risk factor for development of hepatorenal syndrome in cirrhotic patients with acute variceal bleeding George Peter,
More informationHepatology on the AMU
Hepatology on the AMU RCP day, 8 th February 2018 Jo Leithead Consultant in Hepatology and Liver Transplantation Addenbrookes Hospital Cambridge Is liver disease relevant to me? Williams R, Lancet 2014
More informationManaging Cirrhosis. Cirrhosis of the liver is a progressive, fibrosing. Ascites. By Cameron Ghent, MD, FRCPC. Complications of Cirrhosis
Focus on CME at the University of Western Ontario Managing Cirrhosis By Cameron Ghent, MD, FRCPC Cirrhosis of the liver is a progressive, fibrosing process resulting in nodule formation and microvascular
More informationManagement of variceal bleeding Rachael Harry, MA, MRCP, and Julia Wendon, FRCP
Management of variceal bleeding Rachael Harry, MA, MRCP, and Julia Wendon, FRCP Variceal hemorrhage complicates cirrhosis in as many as 50% of patients and results in considerable morbidity and mortality.
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg. Date of FAR:
Core Safety Profile Active substance: Bisoprolol Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg P - RMS: FI/H/PSUR/0002/002 Date of FAR: 13.12.2011
More informationTreatment of portal hypertension
Online Submissions: http://www.wjgnet.com/1007-9327office wjg@wjgnet.com doi:10.3748/wjg.v18.i11.1166 World J Gastroenterol 2012 March 21; 18(11): 1166-1175 ISSN 1007-9327 (print) ISSN 2219-2840 (online)
More informationAcute kidney injury and hepatorenal syndrome in cirrhosis
bs_bs_banner doi:10.1111/jgh.12709 REVIEW ARTICLE Acute kidney injury and hepatorenal syndrome in cirrhosis Mads Egerod Israelsen,* Lise Lotte Gluud and Aleksander Krag* *Department of Gastroenterology,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACLF. See Acute-on-chronic liver failure (ACLF) Acute kidney injury (AKI) in ACLF patients, 967 Acute liver failure (ALF), 957 964 causes
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationCase Report Low-Dose Tolvaptan for the Treatment of Dilutional Hyponatremia in Cirrhosis: A Case Report and Literature Review
Case Reports in Hepatology, Article ID 795261, 4 pages http://dx.doi.org/10.1155/2014/795261 Case Report Low-Dose Tolvaptan for the Treatment of Dilutional Hyponatremia in Cirrhosis: A Case Report and
More informationOptimal management of ascites
Optimal management of ascites P. Angeli, Dept. of Medicine, Unit of Internal Medicine and epatology (), University of Padova (Italy) pangeli@unipd.it 10th Paris epatology Conference National Conference
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Accelerated intravascular coagulation and fibrinolysis (AICF) in liver disease, 390 391 Acid suppression in liver disease, 403 404 ACLF.
More informationMeasurements of portal pressure have wide
Right Atrial Pressure Is Not Adequate to Calculate Portal Pressure Gradient in Cirrhosis: A Clinical-Hemodynamic Correlation Study Vincenzo La Mura, Juan G. Abraldes, Annalisa Berzigotti, Eva Erice, Alexandra
More informationIndications, results and benefits of the measurement of hepatic venous pressure gradient
Indications, results and benefits of the measurement of hepatic venous pressure gradient Poster No.: C-0976 Congress: ECR 2017 Type: Scientific Exhibit Authors: J. P. León Salinas 1, M. D. Ferrer-Puchol
More informationSystemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis
168 Original Article Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis Ramin Behroozian 1*, Mehrdad Bayazidchi 1, Javad Rasooli 1 1. Department
More informationClinical Trials & Endpoints in NASH Cirrhosis
Clinical Trials & Endpoints in NASH Cirrhosis April 25, 2018 Peter G. Traber, MD CEO & CMO, Galectin Therapeutics 2018 Galectin Therapeutics NASDAQ: GALT For more information, see galectintherapeutics.com
More informationAngina pectoris due to coronary atherosclerosis : Atenolol is indicated for the long term management of patients with angina pectoris.
Lonet Tablet Description Lonet contains Atenolol, a synthetic β1 selective (cardioselective) adrenoreceptor blocking agent without membrane stabilising or intrinsic sympathomimetic (partial agonist) activity.
More informationDetection of Esophageal Varices Using CT and MRI
Dig Dis Sci (2011) 56:2696 2700 DOI 10.1007/s10620-011-1660-8 ORIGINAL ARTICLE Detection of Esophageal Varices Using CT and MRI Michael J. Lipp Arkady Broder David Hudesman Pauline Suwandhi Steven A. Okon
More informationThe current recommended prophylaxis of variceal. Long-Term Follow-up of Hemodynamic Responders to Pharmacological Therapy After Variceal Bleeding
Long-Term Follow-up of Hemodynamic Responders to Pharmacological Therapy After Variceal Bleeding Salvador Augustin, 1 Antonio Gonzalez, 1 Laia Badia, 1 Laura Millan, 1 Aranzazu Gelabert, 2 Alejandro Romero,
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationNon tumoral portal vein thrombosis during cirrhosis: Should anticoagulation be proposed?
Full Text Article Open Access Original Article Non tumoral portal vein thrombosis during cirrhosis: Should anticoagulation be proposed? Bibani Norsaf 1,2, Trad Dorra 1,2*, Bejaoui Mohamed 1,2, Sabbeh Mariem
More informationKing Abdul-Aziz University Hospital (KAUH) is a tertiary
Modelling Factors Causing Mortality in Oesophageal Varices Patients in King Abdul Aziz University Hospital Sami Bahlas Abstract Objectives: The objective of this study is to reach a model defining factors
More informationJMSCR Vol 05 Issue 11 Page November 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i11.33 Prevalence of Hyponatremia among patients
More informationProgram Disclosure. This program is supported by an educational grant from Salix Pharmaceuticals.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship
More informationEDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1187 1191 EDUCATION PRACTICE Management of Refractory Ascites ANDRÉS CÁRDENAS and PERE GINÈS Liver Unit, Institute of Digestive Diseases, Hospital Clínic,
More informationRisk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis
Original Article Page 1 of 9 Risk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis Rui Sun*, Xingshun Qi* #, Deli Zou, Xiaodong Shao, Hongyu Li, Xiaozhong
More information